Note: This Press Release contains amendments to the press release previously issued on Nov. 19, ...
· Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and ...
· Patient dosing is underway in a combination study of Bria-IMT™ with KEYTRUDA® (by Merck ...
· BriaCell has achieved positive proof of concept in the Phase IIa study of Bria-IMT™ ...
– Scientific findings will discuss circulating tumor cells as a biomarker of tumor response, which ...
• The addition of the Cancer Center of Kansas (CCK) as a new clinical trial ...
To listen to the Webinar, please kindly click on the following link: http://cc.readytalk.com/play?id=fvx4z8 ...
BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...
(Accesswire — June 13, 2018) – BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V: BCT) (OTCQB:BCTXF), an immuno-oncology ...
BERKELEY, Calif. and VANCOUVER, British Columbia, May 29, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...
Accessibility Tools